Non-opioid painkiller developer Latigo (LTGO.US) seeks to ride the biotech IPO boom with an offering priced at $18 per share, aiming to raise $346 millions

智通财经APP reports that Latigo Biotherapeutics, a biotech company focused on developing non-opioid acute and chronic pain therapies and nearing Phase III clinical trials, has priced its US IPO at $18 per share, at the high end of the previously announced $16-18 price guidance range. The company plans to issue 19.2 million shares (the final offering size is 27% larger than originally planned), raising $346 million. Latigo Biotherapeutics intends to list on Nasdaq under the ticker “LTGO”.